Dermavant Sciences, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Dermavant Sciences, Inc. | DRMT - NASDAQ |
Postponed | $0.00 | $0.00 | Postponed | 6/20/2019 |
| Jefferies, SVB Leerink, Guggenheim Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): FIled 2019-05-24 Terms Added 2019-06-10 | ||||||
About Dermavant Sciences, Inc. (adapted from Dermavant Sciences, Inc. prospectus):
They are a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "DRMT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.